Overview

Tamoxifen With or Without Combination Chemotherapy in Treating Postmenopausal Women With Operable Invasive Breast Cancer

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
Female
Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen. Combining combination chemotherapy with hormone therapy may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of tamoxifen with or without combination chemotherapy in treating postmenopausal women with stage I or stage II breast cancer that can be surgically removed.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Scottish Cancer Therapy Network
Treatments:
Cyclophosphamide
Fluorouracil
Methotrexate
Tamoxifen
Criteria
DISEASE CHARACTERISTICS: Histologically proven unilateral, invasive breast cancer Stage
T0-3, N0-1, M0 No evidence of distant disease, including ipsilateral supraclavicular node
enlargement unless proven benign No carcinoma in situ alone, including Paget's disease of
the nipple without underlying invasion No evidence of distant disease, including
ipsilateral supraclavicular node enlargement unless proven benign No history of pure
carcinoma in situ in either breast Hormone receptor status: Not specified

PATIENT CHARACTERISTICS: Age: 70 and under Sex: Female Menopausal status: Postmenopausal,
defined by 1 of the following criteria: Last menstrual period more than 1 year before
initial surgery Any age with prior bilateral oophorectomy (for nonmalignant reason) Age 50
and over with prior hysterectomy (for nonmalignant reason) without oophorectomy If at
variance with the above definitions, hormonal assays in postmenopausal range take
precedence Performance status: Not specified Life expectancy: Not specified Hematopoietic:
Not specified Hepatic: Not specified Renal: Not specified Other: No other serious illness
No other prior invasive malignancy except adequately treated basal cell or squamous cell
skin cancer

PRIOR CONCURRENT THERAPY: Not specified